CLAIMS

1. A composition comprising Baclofen and Acamprosate for use in the treatment of a neurological disorder in a subject in need thereof.

2. A composition for use according to claim 1, further comprising at least one compound selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Aminocaproic acid, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, Bromocriptine or Torasemide.

3. The composition for use according to claim 1 or 2, wherein said composition comprises at least one of the following combinations of compounds:
   Baclofen and Acamprosate,
   Baclofen and Acamprosate and Diethylcarbamazine,
   Baclofen and Acamprosate and Cinacalcet,
   Baclofen and Acamprosate and Sulfisoxazole,
   Baclofen and Acamprosate and Torasemide,
   Baclofen and Acamprosate and Ifenprodil,
   Baclofen and Acamprosate and Mexiletine,
   Baclofen and Acamprosate and Eplerenone,
   Baclofen and Acamprosate and Levosimendan,
   Baclofen and Acamprosate and Terbinafine, or
   Baclofen and Acamprosate and Leflunomide.

4. A composition for use according to claim 1, comprising Baclofen and Acamprosate as the only active agent.

5. The composition for use of any one of the preceding claims, which further comprises a pharmaceutically acceptable carrier or excipient.

6. The composition of any one of the preceding claims, wherein the neurological disorder is selected from neurodegenerative diseases, neuropathies, substances abuse or spinal cord injury.

7. The composition of any one of the preceding claims, wherein the neurodegenerative disorder is selected from Alzheimer's disease, Alzheimer's related diseases, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease.

8. The composition for use of any one of the preceding claims, wherein the compounds in said composition are formulated or administered together, separately or sequentially.

9. The composition for use of any one of the preceding claims, wherein said composition is administered repeatedly to the subject.

10. The composition for use of any one of the preceding claims, wherein the ratio Acamprosate/Baclofen (W:W) is comprised between 0.05 and 1000.

11. The composition for use of any one of the preceding claims, wherein the dose of Baclofen is less than 100 mg/day.

12. The composition for use of any one of the preceding claims, wherein the dose of Acamprosate is less than 1000 mg/day.

13. The composition for use of any one of the preceding claims, wherein a calcium salt of acamprosate is used.

14. A composition comprising Baclofen and Acamprosate.

Claims

1. Use of a composition comprising Baclofen and Acamprosate, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for treating Alzheimer's disease or a related disease selected from senile dementia of AD type (SDAT), Lewis body dementia, mild cognitive impairment (MCI) and age-associated memory impairment (AAMI).

2. The use of claim 1, wherein the composition further comprises at least one additional compound selected from the group consisting of Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Aminocaproic acid, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, Bromocriptine or Torasemide, or pharmaceutically acceptable salts thereof.

3. The use of claim 1 or 2, wherein the composition further comprises at least:

Baclofen and Acamprosate,
Baclofen and Acamprosate and Diethylcarbamazine,
Baclofen and Acamprosate and Cinacalcet,
Baclofen and Acamprosate and Sulfisoxazole,
Baclofen and Acamprosate and Torasemide,
Baclofen and Acamprosate and Ifenprodil,
Baclofen and Acamprosate and Mexiletine,
Baclofen and Acamprosate and Eplerenone,
Baclofen and Acamprosate and Levosimendan,
Baclofen and Acamprosate and Terbinafine, or
Baclofen and Acamprosate and Leflunomide,
or pharmaceutically acceptable salts thereof.

4. The use of claim 1, wherein the composition further comprises at least:

-Baclofen, Acamprosate and Donepezil,
-Baclofen, Acamprosate and Rivastigmine, or
-Baclofen, Acamprosate and Memantine,

or pharmaceutically acceptable salts thereof.

5. The use of claim 1, wherein the composition comprises Baclofen and Acamprosate as the only active agents.

6. The use of anyone of claims 1 to 5, wherein the compounds are mixed with a pharmaceutically acceptable carrier or excipient.

7. The use of anyone of claims 1 to 6, wherein the compounds are formulated or administered together, separately or sequentially.

8. The use of anyone of claims 1 to 7, wherein the compounds are administered repeatedly to the subject.

9. The use of anyone of claims 1 to 8, wherein the ratio of Acamprosate/Baclofen (W:W) is comprised between 0.05 and 1000.

10. The use of anyone of claims 1 to 9, wherein the dose of Baclofen is less than 100 mg/day.

11. The use of anyone of claims 1 to 10, wherein the dose of Acamprosate is less than 1000 mg/day.

12. The use of anyone of claims 1 to 11, wherein a calcium salt of acamprosate is used.

13. Use of Baclofen, or a pharmaceutically acceptable salt thereof, in combination with at least Acamprosate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating Alzheimer's disease or a related disease selected from senile dementia of AD type (SDAT), Lewis body dementia, mild cognitive impairment (MCI) and age-associated memory impairment (AAMI).

14. Use of Baclofen, or a pharmaceutically acceptable salt thereof, in combination with at least Acamprosate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for improving cognitive symptoms in a subject suffering from, predisposed to, or suspected to suffer from Alzheimer's disease.

15. Use of Baclofen, or a pharmaceutically acceptable salt thereof, in combination with at least Acamprosate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for protecting neuronal cells against amyloid beta and/or glutamate toxicity, in a subject suffering from, predisposed to, or suspected to suffer from Alzheimer's disease.

16. A composition comprising Baclofen, Acamprosate and Donepezil, or pharmaceutically acceptable salts thereof.

17. The use of claim 11, wherein the dose of Acamprosate is comprised between 1 and 400 mg/day, preferably between 1 and 200 mg/day.

18. The use of claim 17, wherein the dose of Acamprosate is comprised between 1 and 50 mg/day.

19. A composition comprising Baclofen and Acamprosate, or pharmaceutically acceptable salts thereof, for use in treating Alzheimer's disease or a related disease selected from senile dementia of AD type (SDAT), Lewis body dementia, mild cognitive impairment (MCI) and age-associated memory impairment (AAMI).

20. Baclofen, or a pharmaceutically acceptable salt thereof, in combination with at least Acamprosate, or a pharmaceutically acceptable salt thereof, for use in treating Alzheimer's disease or a related disease selected from senile dementia of AD type (SDAT), Lewis body dementia, mild cognitive impairment (MCI) and age-associated memory impairment (AAMI).

21. Baclofen, or a pharmaceutically acceptable salt thereof, in combination with at least Acamprosate, or a pharmaceutically acceptable salt thereof, for use in improving cognitive symptoms in a subject suffering from, predisposed to, or suspected to suffer from Alzheimer's disease.

22. Baclofen, or a pharmaceutically acceptable salt thereof, in combination with at least Acamprosate, or a pharmaceutically acceptable salt thereof, for use in protecting neuronal cells against amyloid beta and/or glutamate toxicity, in a subject suffering from, predisposed to, or suspected to suffer from Alzheimer's disease.